Literature DB >> 20732920

T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells.

Claudia Hofmann1, Nadja Dunger, Nicole Grunwald, Günter J Hämmerling, Petra Hoffmann, Jürgen Schölmerich, Werner Falk, Florian Obermeier.   

Abstract

BACKGROUND: Oligodeoxynucleotides (ODNs) containing unmethylated cytosine-guanosine (CpG) sequence motifs constitute the immunostimulatory components of bacterial DNA which potently activate innate immunity. Administration of CpG-ODNs before the onset of experimental colitis prevents intestinal inflammation by induction of colitis-suppressing T cells. AIMS: To identify the interplay between innate and adaptive immune cells finally leading to protective CpG-ODN effects in intestinal inflammation.
METHODS: Total splenic cells or purified selected cell types (CD4(+)CD62L(+) T cells alone or with B cells or dendritic cells (DCs)) from BALB/c mice were (co)-incubated in vitro with CpG-ODN for 5 days and CD4(+)CD62L(+) cells were injected intraperitoneally into C.B.-17 SCID (severe combined immunodeficiency) mice. Splenic CD4(+)CD62L(+) T cells were isolated from transgenic donor mice in which CD11c(+) DCs were depleted by diphtheria toxin administration during CpG-ODN treatment and injected into C57BL/6 Rag2(-/-) recipients. Intestinal inflammation was evaluated by histological scoring and cytokine secretion of mesenteric lymph node cells.
RESULTS: CpG-ODN treatment of total splenic cells but not of purified CD4(+)CD62L(+) cells reduced the colitogenic potential of transferred T cells. While CpG-ODN stimulation of co-cultured CD4(+)CD62L(+) and B-cells did not alter the colitogenic potential of T cells, co-incubation of CpG-ODN-stimulated DCs and CD4(+)CD62L(+) cells reduced the colitogenic potential of the T cell population. Depletion of CD11c(+) DCs during CpG-ODN administration in vivo abolished the protective CpG-ODN effects.
CONCLUSIONS: CpG-ODN-dependent protective effects in experimental colitis act indirectly on CD4(+)CD62L(+) T cells. While the involvement of B cells could be excluded, CD11c(+) DCs were identified as key mediators of CpG-ODN-induced protection in experimental colitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732920     DOI: 10.1136/gut.2009.193177

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

Review 1.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

Review 2.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

3.  Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Authors:  Iris Dotan; Etgar Levy-Nissenbaum; Yehuda Chowers; Alexander Fich; Eran Israeli; Tomer Adar; Shimon Shteingart; Hermona Soreq; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

4.  Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis.

Authors:  Abhisake Kole; JianPing He; Aymeric Rivollier; Danielle D Silveira; Kazuya Kitamura; Kevin J Maloy; Brian L Kelsall
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

Review 5.  The role of type I interferons in intestinal infection, homeostasis, and inflammation.

Authors:  Hyeseon Cho; Brian L Kelsall
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

6.  Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease.

Authors:  E M Giles; T J Sanders; N E McCarthy; J Lung; M Pathak; T T MacDonald; J O Lindsay; A J Stagg
Journal:  Mucosal Immunol       Date:  2016-05-25       Impact factor: 7.313

7.  Inflammatory bowel diseases: when natural friends turn into enemies-the importance of CpG motifs of bacterial DNA in intestinal homeostasis and chronic intestinal inflammation.

Authors:  Florian Obermeier; Claudia Hofmann; Werner Falk
Journal:  Int J Inflam       Date:  2010-08-16

8.  Insulin-like growth factor-1 endues monocytes with immune suppressive ability to inhibit inflammation in the intestine.

Authors:  Rong-Ti Ge; Li-Hua Mo; Ruijin Wu; Jiang-Qi Liu; Huan-Ping Zhang; Zhigang Liu; Zhanju Liu; Ping-Chang Yang
Journal:  Sci Rep       Date:  2015-01-15       Impact factor: 4.379

Review 9.  Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology.

Authors:  Johanna Pott; Silvia Stockinger
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

10.  Therapeutic effect of curcumin on experimental colitis mediated by inhibiting CD8+CD11c+ cells.

Authors:  Hai-Mei Zhao; Fei Han; Rong Xu; Xiao-Ying Huang; Shao-Min Cheng; Min-Fang Huang; Hai-Yang Yue; Xin Wang; Yong Zou; Han-Lin Xu; Duan-Yong Liu
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.